News | July 24, 2025
Pfizer completes licensing agreement with 3SBio to expand oncology portfolio
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks
Clinical data showing unprecedented remission rates in newly diagnosed AML patients support advancing ICT01 into pivotal trials
Loteprednol Etabonate Ophthalmic Suspension, 0.5% is indicated for the treatment of steroidresponsive inflammatory conditions of the palpebral and bulbar conjunctiva
The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026
Milestone also announced the extension of its $75 million Royalty Purchase Agreement with RTW Investments
Celecoxib is a nonsteroidal anti-inflammatory drug
It is intended for contrast enhancement in MRI scans
Apollo AyurVAID’s product line features clinically proven formulations certified safe by NABL-accredited laboratories for heavy metals, aflatoxins, microbial content
Insights are drawn from over 30K+ people across 300+ cities including all metro and tier-1 cities
Subscribe To Our Newsletter & Stay Updated
